Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 2, Février 2002
Page(s) 137 - 139
Section Le Magazine : Nouvelles
DOI http://dx.doi.org/10.1051/medsci/2002182137
Publié en ligne 15 février 2002
  1. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTENdeficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98 : 10314–9.
  2. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice. Proc Natl Acad Sci USA 2001; 98 : 10320–5.
  3. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics : inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98 : 10031–3.
  4. Brooksbank C. Therapeutic targets : withdrawal symptoms. Nat Rev Cancer 2001; 1 : 6–11.
  5. Vanhaesebroeck B, Leevers SJ, Khatereh A, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70 : 535–602.
  6. Stein RC, Waterfield MD. PI 3-kinase inhibition : a target for drug development ? Mol Med Today 2000; 6 : 347–57.
  7. Payrastre B, Missy K, Giuriato S, et al. Phosphoinositides : key players in cell signalling, in time and space. Cell Signal 2001; 13 : 377–87.
  8. Di Cristofano A, Pandolfi PP. The multiples roles of PTEN in tumor suppression. Cell 2000;100 : 387–90.
  9. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC gene : a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91 : 1922–32.
  10. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin :novel phosphoinositide phosphatases. Annu Rev Biochem 2001; 70 : 247–79